share_log

IFabric Announces 2024 Annual General and Special Meeting Voting Results

IFabric Announces 2024 Annual General and Special Meeting Voting Results

IFabric宣佈2024年股東年會和特別會議的投票結果
Accesswire ·  06/26 06:30

MARKHAM, ON / ACCESSWIRE / June 26, 2024 / iFabric Corp. (TSX:IFA)(OTCQX:IFABF) ("iFabric") is pleased to announce that at its annual general and special meeting of shareholders, held on June 25, 2024, shareholders voted in favour of all resolutions brought before the meeting. A detailed description of all resolutions that were voted on can be reviewed in iFabric's information circular which was filed on on May 29, 2024. All of the director nominees listed in the information circular were re-elected as directors of iFabric. The detailed results of the vote are set out below:

2024年6月26日,加拿大馬克漢市/ ACCESSWIRE / iFabric股份有限公司(TSX:IFA)(OTCQX:IFABF)(以下簡稱"iFabric")很高興地宣佈,在2024年6月25日舉行的股東年度大會上,股東們贊成了提交給大會的所有決議。有關投票的所有決議的詳細說明可以在iFabric於2024年5月29日提交的信息通函中查看。通函中提名的所有董事候選人都被連任爲iFabric的董事。投票的詳細結果如下所示:

Nominee

Votes For

% Votes For

Votes Withheld

% Votes Withheld

Hylton Karon

19,923,766

99.89%

21,300

0.11%

Hilton Price

19,921,766

99.88%

23,300

0.12%

Richard Macary

19,754,259

99.04%

190,807

0.96%

Cameron Groome

19,754,259

99.04%

190,807

0.96%

Mark Cochran

19,738,159

98.96%

206,907

1.04%

Giancarlo Beevis

19,918,766

99.87%

27,300

0.13%

提名人

已投票支持

%投票贊成

已投票反對

棄權票佔總票數的%

Hylton Karon

19,923,766

99.89%

21,300

0.11%

Hilton Price

19,921,766

99.88%

23,300

0.12%

Richard Macary

19,754,259

99.04%

190,807

0.96%

Microbix Biosystems Inc.是一個爲人類健康創建專有生物產品的企業,擁有100多名技術嫺熟的員工和已達到每月2,000萬加元的年銷售額。它製造和出口全球診斷行業的各種關鍵成分和設備,尤其是免疫測定的抗原和支持臨床實驗室熟練度測試、啓用檢測和驗證,或幫助確保臨床診斷工作流程的實驗室質量評估產品(QAP)。其抗原推動着約100家診斷製造商的抗體測試,而QAP則銷售給臨床實驗室認證組織、診斷公司和臨床實驗室。Microbix QAPs現在在30多個國家/地區可用,並由國際分銷商網絡提供支持。Microbix已獲得ISO 9001和13485認證、美國FDA註冊、澳大利亞TGA註冊、加拿大衛生部門執照,並提供CE標記產品。

19,754,259

99.04%

190,807

0.96%

Mark Cochran

19,738,159

98.96%

206,907

1.04%

Giancarlo Beevis

19,918,766

99.87%

27,300

0.13%

In addition, at the meeting, iFabric shareholders approved resolutions to fix the number of directors at six, approve the unallocated stock options for a further three years, and in respect of the appointment of BDO Canada LLP, Chartered Professional Accountants, as the auditors of iFabric for the ensuing year.

此外,在會議上,iFabric股東批准了將董事會人數定爲六人,將未分配的期權批准爲再延長三年,並且關於指定加拿大BDO有限公司爲iFabric至下一年的核數師的決議。

About iFabric Corp.

關於iFabric Corp.

Headquartered in Markham, Ontario, iFabric, , is listed on the TSX and, currently has 30.3 million shares issued and outstanding. Its two strategic divisions offer a variety of products and services through wholly-owned subsidiaries, namely, Intelligent Fabric Technologies (North America) Inc. ("IFTNA") and Coconut Grove Pads Inc. ("Coconut Grove").

iFabric公司總部位於安大略省馬克漢,目前在TSX上市,已發行和流通股份3030萬股。其兩個戰略部門通過全資子公司,即Intelligent Fabric Technologies(North America)公司(以下簡稱IFTNA)和Coconut Grove Pads公司(以下簡稱Coconut Grove),提供各種產品和服務。IFTNA專注於高性能體育服裝、醫療防護服裝、消費者防護服裝以及提供給織物、泡沫、塑料的"智能"處理的專有技術。

IFTNA is focused on development and sale of high-performance sports apparel, medical protective apparel, consumer protective apparel, and proprietary treatments that provide "intelligent" properties to fabrics, foams, plastics, and numerous other surfaces, thereby improving the safety and well-being of the user. Such intelligent properties include antiviral and antibacterial characteristics, water-repellence and UV protection, among others.

IFTNA專注於開發和銷售高性能運動服裝、醫療保護服裝、消費者保護服裝和專有處理技術,爲織物、泡沫、塑料等材料提供“智能”特性。 以及許多其他表面 從而提高用戶的安全和福利。這些智能特性包括抗病毒和抗菌特性、防水和紫外線保護等。

Coconut Grove, operating as Coconut Grove Intimates, is a designer, manufacturer, distributor, licensor and licensee of ladies' intimate apparel products and accessories.

椰林灣(Coconut Grove)作爲椰林灣貼身衣物、內衣產品和附件的設計師、製造商、經銷商、授權方和被授權方。

FOR FURTHER INFORMATION, please contact:

如需更多信息,請聯繫:

Hilton Price, CFO
Tel: 647.465.6161
Email: hilton.price@rogers.com

Hilton Price,首席財務官
電話:647.465.6161
電子郵件:hilton.price@rogers.com

SOURCE: iFabric Corp

來源:iFabric Corp


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論